No Known Mutations

IRB# 19388 A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

IRB# 21194 study A phase 1 study of SGN-CD228A in select advanced solid tumors

IRB# 21508 Study of ORIC-101 in Combination With Anticancer Therapy

IRB# 21464 A Study of mRNA-2752 for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade

IRB# 21766 A Phase i/b study of GEN-001 in Combination with Avelumab in Patients with Advanced Solid Tumors Who Have Progressed during or after Treatment with Anti-PD-(L)1 therapy

IRB# 22760 A Phase 1b Dose Escalation Study to evaluate GS-3583, a FLT3 agonist Fc fusion protein, in Subjects with Advanced Solid Tumors

IRB# 22602 Study of Magrolimab in Participants With Solid Tumors

IRB# 23157 Study of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

IRB# 23236 Study of SGN-STNV in Advanced Solid Tumors

IRB 24893 A Phase 1/2a, First-in-Human (FiH), Open-Label, Dose-Escalation and Dose Expansion Study of IMT-009 in Patients with Advanced Solid Tumors

IRB 24483 Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors

IRB 24406 A PHASE 1 STUDY OF KSO-4279 ALONE AND IN COMBINATION WITH ADVANCED SOLID TUMORS

IRB 24635 Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)

IRB 24649 An open-label, master protocol to study Datopotamab Deruxtecan (Dato-DXd) alone and in combination with anticancer agents in patients with advanced/metastatic solid tumors

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php
Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view.

**Fusion-NTRK (previously treated)**

- **IRB# 17674**
  Loxo-195 in fusion-NTRK (previously treated) solid tumors

- **IRB# 16676**
  BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors

**RET Mutations**

- **IRB# 18164**
  A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

**Solid tumors with gene aberrations in the mitogen-activated protein kinase (MAPK) pathway**

- **IRB 21548**
  A Phase 1 Study of AMG 650 in Subjects With Advanced Solid Tumors

- **IRB 21819**
  A Phase 1-2 Study of ASTX029 in Subjects With Advanced Solid Tumors

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

9/15/2022

http://www.ohsu.edu/research/rda/so/knight.php